Obeticholic acid (OCA), a synthetic derivative of bile acids and a potent, selective farnesoid X receptor (FXR) agonist, received U.S. Food and Drug Administration (FDA) approval in 2016 for use alongside UDCA in the treatment of PBC [11]. This evidence concerns the gene NR1H4 and primary biliary cholangitis.